Edition:
United Kingdom

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

110.50EUR
3:32pm BST
Change (% chg)

€1.60 (+1.47%)
Prev Close
€108.90
Open
€110.50
Day's High
€111.60
Day's Low
€109.10
Volume
56,525
Avg. Vol
151,020
52-wk High
€114.60
52-wk Low
€76.45

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Overall

Beta: 0.78
Market Cap(Mil.): €2,171.58
Shares Outstanding(Mil.): 29.35
Dividend: --
Yield (%): --

Financials

  MORG.DE Industry Sector
P/E (TTM): -- 69.38 32.67
EPS (TTM): -2.61 -- --
ROI: -19.28 8.94 14.48
ROE: -19.78 10.07 15.78

CORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue Guidance

* Financial year 2019 guidance, updated in July, confirmed: revenues in range of 65 mln to 72 mln eur

07 Aug 2019

German stocks - Factors to watch on May 22

BERLIN/FRANKFURT, May 22 The following are some of the factors that may move German stocks on Wednesday:

22 May 2019

German stocks - Factors to watch on April 30

BERLIN, April 30 The following are some of the factors that may move German stocks on Tuesday:

30 Apr 2019

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

24 Apr 2019

German biotech group Morphosys seeks European partner for debut drug

FRANKFURT, Feb 25 German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.

25 Feb 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates